link.springer.com

Cardiac safety of liposomal anthracyclines - Cardiovascular Toxicology

  • ️Batist, Gerald
  • ️Wed Apr 25 2007

References

  1. Knoop, A. S. et al. (2005). Retrospective analysis of topoisomerase IIa amplifications and delections as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. Journal of Clinical Oncology, 23(30), 7483–7490.

    Article  PubMed  CAS  Google Scholar 

  2. Pritchard, K. I., Shepherd, L. E., O’Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006). National cancer institute of Canada clinical trials group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. The New England Journal of Medicine, 354(20), 2103–2111.

    Article  PubMed  CAS  Google Scholar 

  3. Slamon D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344, 783–792.

    Google Scholar 

  4. Swenson, C. E., Bolcsak, L. E., Batist, G., Guthrie, T. H. Jr Tkaczuk, K. H., Boxenbaum, H., Welles, L., Chow, S. C., Bhamra, R., & Chaikin, P. (2003). Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs, 14(3), 239–246.

    Article  PubMed  CAS  Google Scholar 

  5. Overmoyer, B., Silverman, P., Holder, L. W., Tripathy, D., & Henderson, I. C. (2005). Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clinical Breast Cancer, 6(2), 150–157.

    Article  PubMed  CAS  Google Scholar 

  6. Chia, S., Clemons, M., Martin, L. A., Rodgers, A., Gelmon, K., Pond, G. R., & Panasci. L. (2006). Pegylated liposomal doxorubicin and Trastuzumab in Her-2 overexpressing metastatic breast cancer: A multicentre phase II trial. Journal of Clinical Oncology, 24(18), 2773–2778.

    Article  PubMed  CAS  Google Scholar 

  7. Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A, Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer. K., Tkaczuk, K., Park. Y. C., & Lee, L. W. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of Clinical Oncology, 19(5), 1444–1454.

    PubMed  CAS  Google Scholar 

  8. Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., & Winer, E. (2002). TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94(1), 25–36.

    Article  PubMed  CAS  Google Scholar 

  9. Batist, G., Harris, L., Azarnia, N., Lee, L. W., & Daza-Ramirez. P. (2006). Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: Results of a retrospective analysis. Anticancer Drugs, 17(5), 587–595.

    Article  PubMed  CAS  Google Scholar 

  10. Baselga et al. (2005) Phase II trial of Taxol, Trastuzumab plus non-pegylated liposomal doxorubicin in locally advanced and metastatic breast cancer. ASCO.

Download references